— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share
— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected
— Net loss before recognition of the deemed dividends was $5.3 million
— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018
— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin
— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor
Most Popular
Infographic: How Starbucks (SBUX) performed in Q1 2023
Starbucks Corporation (NASDAQ: SBUX) reported first quarter 2023 earnings results today. Consolidated net revenues increased 8% year-over-year to $8.7 billion, in line with projections. Global comparable store sales increased
Earnings: Google parent Alphabet (GOOG, GOOGL) reports lower Q4 profit
Alphabet Inc. (NASDAQ: GOOGL, GOOG) on Thursday reported a 1% increase in fourth-quarter 2022 revenues, with strong contributions from the cloud business. The company, which owns the largest internet search
HOG Earnings: Key quarterly highlights from Harley-Davidson’s Q4 2022 financial results
Harley-Davidson, Inc. (NYSE: HOG) reported fourth quarter 2022 earnings results today. Revenue increased 12% year-over-year to $1.14 billion. Net income attributable to Harley-Davidson, Inc. rose 94% YoY to $42 million,